Motley Fool Australia
  •  

    Notifications

    Scott

    Wondering where you should invest $1,000 right now?

    Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly!

    Learn More
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Race Oncology Ltd (ASX: RAC)
    3. /

Race Oncology Ltd (ASX: RAC) Share Price and News

Price

$1.185

Movement

0.005 (+0.42%)

As at 6 Jun - Closed (20 mins delayed)

52 Week Range

$0.92 - $2.09

 
1 Year Return

-32.29%

Race Oncology Ltd Chart and Price Data

2025
2025
2025
2025
$0.50
$1.00
$1.50
$0.50
$1.00
$1.50
$0.50
$1.00
$1.50
$0.50
$1.00
$1.50

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $205.87 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 173.73 million
Earnings per share -0.047
Dividend per share N/A
Year To Date Return -12.22%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-12.22%

Shares Outstanding

173.73 million

Earnings per share

-0.047

Share Price

$1.185

Day Change

0.005 (+0.42%)

52 Week Range

$0.92 - $2.09

Yesterday's Close

$1.18

Today's Open

$1.195

Days Range

$1.17 - $1.195

Volume

47,710

Avg. Volume (1 month)

115,703

Turnover

$56,513

As at 6 Jun - Closed

    • Race Oncology Ltd (ASX: RAC)
    Latest News

    Female doctor with a mask holds out hand in a stop gesture.
    Healthcare Shares

    Why is the Race Oncology share price in a trading halt?

    | Aaron Teboneras

    Race Oncology is set to release some trial results to the market in the coming days.

    Read more »

    A woman looks distressed as she stares dramatically at her phone
    Share Market News

    5 ASX shares making unbelievable news this week

    | Tristan Harrison

    These five ASX shares made headlines this week.

    Read more »

    Female scientist working in laboratory for Race Oncology
    Healthcare Shares

    'Compelling results': Here's why the Race Oncology (ASX:RAC) share price is rocketing 5%

    | Zach Bristow

    The biotech company is on the share price racetrack again today – and leading its ASX peers.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Share Gainers

    Why did Race Oncology (ASX:RAC) shares bounce 14% higher on Wednesday?

    | Zach Bristow

    We analyse what's underlying the gains that were made today.

    Read more »

    A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
    Healthcare Shares

    Why did the Race Oncology (ASX:RAC) share price drop 10% today?

    | Sebastian Bowen

    What happened with Race shares today?

    Read more »

    Lab technician analyses a sample in a laboratory for a clinical trial
    Healthcare Shares

    Race Oncology (ASX:RAC) share price rises following preclinical discovery

    | Alice de Bruin

    Shares in the oncology provider are up following an exciting discovery...

    Read more »

    A health professional wearing green scrubs and a face mask and stethoscope uses his mobile phone.
    Healthcare Shares

    In the green: Here are the 5 best ASX healthcare shares of 2021

    | Zach Bristow

    ASX healthcare shares were a strong bunch last year, with several majors and minors outperforming the primary indices.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Here's why the Race Oncology (ASX:RAC) share price is edging higher

    | Aaron Teboneras

    The pharmaceutical company's shares are picking up steam on Tuesday. Here are the details

    Read more »

    A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
    Healthcare Shares

    Here's why the Race Oncology (ASX:RAC) share price is climbing today

    | Monica O'Shea

    Why is Race Oncology making the heart tick today?

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Healthcare Shares

    Why is the Race Oncology (ASX:RAC) share price plunging 12% today?

    | Zach Bristow

    It hasn't been a good day for the precision oncology company.

    Read more »

    ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
    Share Fallers

    Why Bapcor, Mayne Pharma, Race Oncology, and TechnologyOne shares are sinking

    | James Mickleboro

    These ASX shares are falling on Wednesday...

    Read more »

    man jumping along increasing bar graph signifying jump in alumina share price
    Healthcare Shares

    Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough

    | Zach Bristow

    It was a good day for the healthcare company.

    Read more »

    Frequently Asked Questions

    RAC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    6th Jun 2025 2025-06-06T11:54:11 Application for quotation of securities - RACYesNo11:54am818k
    3rd Jun 2025 2025-06-03T10:27:36 Notification of cessation of securities - RACYesNo10:27am514k
    2nd Jun 2025 2025-06-02T12:14:32 Race Gold Coast Brisbane Investor EventsYesNo12:14pm2193k
    29th May 2025 2025-05-29T16:11:17 Application for quotation of securities - RACYesNo4:11pm818k
    22nd May 2025 2025-05-22T11:14:56 Application for quotation of securities - RACYesNo11:14am818k
    7th May 2025 2025-05-07T11:09:59 Application for quotation of securities - RACYesNo11:09am818k
    6th May 2025 2025-05-06T15:51:28 Notification of cessation of securities - RACYesNo3:51pm514k
    5th May 2025 2025-05-05T08:57:55 Race Announces Key Senior Clinical Team AppointmentsYesNo8:57am3199k
    1st May 2025 2025-05-01T08:57:35 First Patient Dosed Safely in RC220 Phase 1 TrialYesNo8:57am3204k
    23rd Apr 2025 2025-04-23T08:41:36 March 2025 Quarterly Activity Report and Appendix 4CYesNo8:41am9517k

    About Race Oncology Ltd

    Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.

    Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.

    The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

    As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.

    RAC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Jun 2025 $1.19 $0.01 0.85% 47,710 $1.20 $1.20 $1.17
    05 Jun 2025 $1.18 $-0.01 -0.84% 58,677 $1.20 $1.20 $1.18
    04 Jun 2025 $1.19 $0.01 0.85% 62,420 $1.19 $1.21 $1.17
    03 Jun 2025 $1.18 $-0.03 -2.48% 85,664 $1.21 $1.25 $1.16
    02 Jun 2025 $1.21 $-0.07 -5.47% 85,937 $1.28 $1.28 $1.20
    30 May 2025 $1.28 $-0.05 -3.75% 103,870 $1.36 $1.36 $1.25
    29 May 2025 $1.34 $-0.05 -3.60% 10,571 $1.40 $1.40 $1.34
    28 May 2025 $1.39 $0.02 1.47% 87,966 $1.37 $1.39 $1.33
    27 May 2025 $1.37 $-0.02 -1.44% 65,938 $1.39 $1.39 $1.30
    26 May 2025 $1.39 $-0.03 -2.11% 59,395 $1.42 $1.45 $1.38
    23 May 2025 $1.42 $0.03 2.16% 29,574 $1.41 $1.42 $1.39
    22 May 2025 $1.39 $0.02 1.46% 87,815 $1.39 $1.42 $1.37
    21 May 2025 $1.37 $0.00 0.00% 46,051 $1.38 $1.40 $1.37
    20 May 2025 $1.37 $-0.04 -2.84% 102,552 $1.44 $1.44 $1.35
    19 May 2025 $1.41 $-0.04 -2.77% 199,196 $1.47 $1.50 $1.41
    16 May 2025 $1.45 $0.03 2.11% 171,242 $1.43 $1.49 $1.42
    15 May 2025 $1.42 $0.03 2.16% 166,304 $1.43 $1.45 $1.37
    14 May 2025 $1.39 $0.04 2.96% 187,536 $1.43 $1.43 $1.36
    13 May 2025 $1.35 $0.02 1.50% 301,646 $1.41 $1.49 $1.34
    12 May 2025 $1.33 $0.09 7.23% 409,319 $1.26 $1.42 $1.25
    09 May 2025 $1.25 $0.02 1.63% 134,171 $1.24 $1.28 $1.22

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Nov 2024 Serge Scrofani Issued 58,446 $82,408
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Megan Baldwin Non-Executive Director Jan 2025
    Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She is the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases. Her experience includes 10 years as CEO and Managing Director of Opthea. Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentechs commercial division. Dr Baldwins experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentechs early stage oncology programs. Dr Baldwin has corporate governance experience and currently serves on the boards of Anaxis Pharma and Gertrude Biomedical, and is a director of Ausbiotech.
    Dr Daniel Tillett Chief Executive OfficerManaging Director Sep 2019
    Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology, pharmacy, microbiology and virology.
    Dr Peter (Pete) Smith Executive DirectorExecutive Chairman Jun 2023
    Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a Pharmaceuticals Analyst with UBS and HSBC, being involved in transactions including LSE/NASDAQ initial public offerings, fundraisings, and mergers & acquisitions (M&A). He is also currently a Director of MycRx Inc. and Amala Therapeutics.
    Dr Serge Scrofani Non-Executive Director Sep 2024
    Dr Scrofani has more than 28 years experience in the healthcare sector, working in global roles across research, strategy and corporate development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives. Prior to this, he led Business Development for CSL Behring based in the US. Serge is currently Principal of Poplar Advisory, a boutique strategic advisory firm focused on the healthcare sector. He is also a Board member of the Burnet Institute and The Centre for Eye Research, and a founding Director of the private equity firm FinCap Pty Ltd.
    Mr Peter Webse Company Secretary Aug 2016
    -
    Michelle Rashford Chief Medical Officer
    -
    Peter Webse Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Daniel Tillett 17,267,615 10.13%
    Mr Phillip Richard Perry 6,334,328 3.72%
    Mr Mark Phillip Juan 5,839,062 3.43%
    The Trust Company (Australia) Limited <Mof A/C> 5,147,246 3.02%
    Biosynergy Partners Pty Ltd 4,855,700 2.85%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient > 2,618,464 1.54%
    Marinella Messina 1,845,245 1.08%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,669,500 0.98%
    Mr Sandor Helby 1,625,000 0.95%
    Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,575,000 0.92%
    Kudoss Investments Pty Ltd <Aitken Global Family A/C> 1,500,000 0.88%
    Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,370,262 0.80%
    Mr Alan Giles Sauran 1,094,368 0.64%
    Mr Brian James Walker 955,000 0.56%
    Pierpont Investments Pty Ltd <Pierpont Super Fund A/C> 950,000 0.56%
    Surpion Pty Ltd <M W Suhr & Co A/C> 935,000 0.55%
    Citicorp Nominees Pty Limited 847,284 0.50%
    Mr Van Quy Do 829,409 0.49%
    Mr Beau Thomas Robinson <Beau Robinson Invstmnt A/C> 743,458 0.44%
    Mr Graeme Stewart Pocknall & Mrs Vivienne Glynis Pocknall 674,511 0.40%

    Profile

    since

    Note